Skip to content

Homepage

Author: Immunocore Holdings plc

Posted Date:

May 31, 2026

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

Immunocore Holdings plc

May 31, 2026
Immunocore reports first quarter financial results and provides a business update

Immunocore Holdings plc

May 7, 2026
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

Immunocore Holdings plc

April 19, 2026
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference

Immunocore Holdings plc

April 6, 2026
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

Immunocore Holdings plc

March 17, 2026
Immunocore to present at upcoming investor conferences

Immunocore Holdings plc

March 3, 2026
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update

Immunocore Holdings plc

February 25, 2026
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025

Immunocore Holdings plc

February 18, 2026
Immunocore announces R&D leadership evolution

Immunocore Holdings plc

January 30, 2026